The increase in the price target by HC Wainwright & Co. reflects a positive outlook on Iovance Biotherapeutics, likely due to strong fundamentals or promising developments within the company. This endorsement from a reputable analyst could lead to increased investor confidence and potentially drive the stock price up in the short term.